The prognostic value of baseline circulating tumor cells in patients with metastatic breast cancer: a meta-analysis

• 作者: Fang-Fang Li Hong-Wei Yang Jia-You Liu Jin-Shui Li Ling-Mi Hou Lu-Lan Pu Mao-Shan Chen Shi-Shan Deng Yu Chen Yu-Qing Zhou
• 来源期刊: TMR临床研究
• 学科: 医学
• 关键词: Circulating tumor cells Metastatic breast cancer PROGNOSIS META-ANALYSIS
• 年，卷（期）: 2020,（4）
• 页码范围: 150-158
• 页数: 9页
• 分类号: R73

摘要

Objective:The prognostic value of circulating tumor cells(CTCs)in metastatic breast cancer(MBC)patients was contentious.A meta-analysis was conducted to evaluate whether MBC patients’clinical outcomes could be predicted by CTCs detection.Methods:Relevant published studies were searched through electronic databases from January 1990 to February 2018,among which,those investigated the correlation between CTCs and clinical outcomes of progression-free survival and overall survival in MBC patients were involved.The hazard ratios(HR)and confidence intervals(CI)in the studies were extracted from the study using random or fixed effects model,and the meta-analysis was conducted.The prognostic value of tumor cells in patients with different subtypes was estimated by subgroup analysis.Results:Twenty-one eligible studies enrolling 3,837 patients were appropriate for pooled analysis.Progression-free survival(HR,1.66;95%CI,1.47–1.87;P=0.000)and overall survival(HR,2.51;95%CI,2.13–2.96;P=0.000)were worse in patients with CTCs-positive.Subtypes of hormone receptor(HorR)positive,human epidermal growth factor receptor-2(HER2)negative and triple negative with presence of CTCs showed a statistically significant worse PFS and OS.However,CTCs detection presented no prognostic value in patients with HorR-negative or HER2-positive subtypes.Conclusion:The enumeration of CTCs at baseline in patients with MBC subtypes of HorR-positive,HER2-negative and triple negative is connected with disease progression and poor survival,but inappropriate for HorR-negative and HER2-positive subtypes.